Amantadine: A review of use in child and adolescent psychiatry

Journal of the Canadian Academy of Child and Adolescent Psychiatry

Volumn 22, Issue 1, 2013, Pages 55-60

  Hosenbocus, Sheik ^a   Chahal, Raj ^a  

^a ROYAL INLAND HOSPITAL   (Canada)

Author keywords

Amantadine; Glutamatergic system; N methyl D aspartate receptor; Pharmacology

Indexed keywords

AMANTADINE; ARIPIPRAZOLE; METHYLPHENIDATE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PLACEBO; RISPERIDONE;

ADOLESCENT; AGITATION; ANOREXIA; ARTICLE; ATTENTION DEFICIT DISORDER; AUTISM; CHILD; CHILD PSYCHIATRY; CLINICAL EFFECTIVENESS; CONFUSION; CONSTIPATION; CREATININE BLOOD LEVEL; DECREASED APPETITE; DELUSION; DEPRESSION; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENURESIS; FETAL ALCOHOL SYNDROME; HALLUCINATION; HUMAN; HYPERTENSION; INSOMNIA; IRRITABILITY; LIVEDO RETICULARIS; LOW DRUG DOSE; MORNING DOSAGE; NAUSEA; NEUROPATHOLOGY; NEUROPROTECTION; OBSESSIVE COMPULSIVE DISORDER; ORTHOSTATIC HYPOTENSION; PARANOIA; PATIENT MONITORING; PATIENT SAFETY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BLOCKING; RECOMMENDED DRUG DOSE; SIDE EFFECT; SLURRED SPEECH; SOMNOLENCE; SUICIDAL IDEATION; SUICIDE ATTEMPT; THOUGHT DISORDER; UREA NITROGEN BLOOD LEVEL; URINE RETENTION; XEROSTOMIA;

EID: 84873644391     PISSN: 17198429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Aoki, F., Sitar, D., & Ogilvie, R. (1979). Amantadine kinetics in healthy young subjects after long-term dosing. Clinical Pharmacology and Therapeutics, 26(6), 729-736.
2. Ambrosini, P., & Fried, J. (1984). Preliminary report: Amantadine Hydrochloride in childhood Enuresis. Journal of Clinical Psychopharmacology, 4(4), 177-240.
3. Bhak, W., Lee, K., Chae, J., Pae, C., Jun, T., & Kim, K. (2004). Open label study of the effect of amantadine on weight gain induced by olanzapine. Psychiatry and Clinical Neuroscience, 58(2), 163-167.
4. Blanpied, T., Clarke, R., & Johnson, J. (2005). Amantadine inhibits NMDA receptors by accelerating channel closure during channel block. The Journal of Neuroscience, 25(13), 3312-3322.
5. Carlsson, M. (1998). Hypothesis: Is infantile autism a hypoglutamatergic disorder? Relevance of glutamine-serotonin interactions for pharmacotherapy. Journal of Neurotransmission, 105 (4-5), 525-535.
6. Chandler, M., Barnhill, J., & Gualtieri, C. (1988). Amantadine for the agitated head-injury patient. Brain Injury, 2(4), 309-311.
7. Cook, P., Dermer, S., & McGurk, T. (1986). Fatal overdose with amantadine. Canadian Journal of Psychiatry, 31(1), 757-758.
8. Correa, N., Opler, L., Kay, S., & Birmaher B. (1987). Amantadine in the treatment of neuroendocrine side effects of neuroleptics. Journal of Clinical Psychopharmacology, 7(2), 91-95.
9. DonFrancesco, R., Calderoni, M., & Vitiello, B. (2007). Open-label Amantadine in children with Attention Deficit/Hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 17(5), 657-663.
10. Drayton, S., Davies, K., Steinber, M., Leroi, I., Rosenblatt, A., & Lyketsos, C. (2004). Amantadine for executive dysfunction syndrome in patients with Dementia. Psychosomatics, 45(3), 205-209.
11. Elbe, D., & Lalani, Z. (2012). Review of the pharmacotherapy of irritability of Autism. Journal of Canadian Academy of Child and Adolescent Psychiatry, 21(2), 130-146.
12. Endo Pharmaceuticals Inc. (2007). Symmetrel (Amantadine) Prescribing Information. Retrieved September 30, 2012, from http://www. symmetrel.com/pdf/access.
13. Ferguson, J., & Shingleton, R. (2007). An open-label, flexible-dose study of Memantine in Major Depressive Disorder. Clinical Neuropharmacology, 30(3), 136-144.
14. Floris, M., Lejeune, J., & Deberdt, W. (2001). Effect of amantadine on weight gain during olanzapine treatment. European Neuropsychopharmacology, 11(2), 181-182.
15. Giacino, J., Whyte, J., Bagiella, E., Kalmar, K., Childs, N., Khademit, A.,Sherer, M. (2012). Placebo-controlled trial of amantadine for severe traumatic brain injury. New England Journal of Medicine, 366(9), 819-826.
16. Gracious, B., Krysiak, T., & Youngstrom, E. (2002). Amantadine treatment of psychotropic-induces weight gain in children and adolescents: Case series. Journal of Child and Adolescent Pscyhopharmacology, 12(3), 249-257.
17. Graham, K., Hongbin, G., Lieberman, J., Harp, J., & Perkins, D. (2005). Double-blind, placebo-controlled investigation of Amantadine for weight loss in subjects who gained weight with Olanzapine. American Journal of Psychiatry, 162(9), 1744-1746.
18. Green, L., Hornyak, J., & Hurvitz, E. (2004). Amantadine in pediatric patients with traumatic brain injury: A retrospective, case-controlled study. American Journal of Physical Medicine and Rehabilitation, 83(12), 893-897.
19. Hallowell, E., & Ratey, J. (2005). Delivered from distraction: Getting the most out of life with Attention Deficit Disorder. United States: Ballentine Books.
20. Hashimoto, K. (2009). Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Research Reviews, 61(2), 105-123.
21. King, B., Wright, M., Handen, B., Sikich, L., Zimmerman, A., McMahon, W.,Cook Jr., E. H. (2001). Double-blind, placebo-controlled study of Amantadine Hydrochloride in the treatment of children with Autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 40(6), 658-665.
22. King, B., Wright, D., Snape, M., & Dourish, C. (2001). Case series: Amantadine open-label treatment of impulsive and aggressive behavior in hospitalized children with developmental disabilities. Journal of the American Academy of Child and Adolescent Psychiatry, 40(6), 654-657.
23. Kornhuber, J., Schoppmeyer, K., & Riderer, P. (1994). Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. Journal of Neural Transmission, 43(Suppl), 91-104.
24. Maayan, L., Vakhrusheva, J., & Correll, C. (2010). Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: A systematic review and meta-analysis. Neuropsychopharmacology, 35(7), 1520-1530.
25. Masters, K. (1997). Alternative medication for ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 36(3), 301-302.
26. Mattes, J. (1980). A pilot trial of Amantadine in hyperactive children. Psychopharmacology Bulletin, 16(3), 67-69
27. Mizoguchi, K., Yokoo, H., Yoshida, Y., Tanaka, T., & Tanaka, M. (1994).Amantadine increases the extracellular dopamine levels in the striatum by re-uptake inhibition and by N-methyl-D-aspartate antagonism. Brain Research, 662(1-2), 255-258.
28. Mohammadi, M. R., Kazemi, M. R., Ebtahal, Z., Rezazadeh, S. A., Tabrizi, M., & Akhondzadeh, S. (2010). Amantadine versus methylphenidate in children and adolescents with attention deficit/ hyperactivity disorder: A randomized, double-blind trial. Human Psychopharmacology, 25(7-8), 560-556.
29. Pasquini, M., Berardelli, I., & Biondi, M. (2010). Amantadine augmentation for refractory Obsessive-Compulsive Disorder: A case report. Journal of Clinical Psychopharmacology, 30(1), 85-86.
30. Rego, M. D., & Giller, E. L. (1989). Mania secondary to amantadine treatment of neuroleptic-induced hyperprolactinemia. Journal of Clinical Psychiatry, 50(4), 143-144.
31. Reiff, M. (2001). Journal Article Reviews: Autism. Journal of Developmental and Behavioral Pediatrics, 22(5), 339-340.
32. Rogoz, Z., Skuza, G., Daniel, W., Wojcikowski, J., Dudek, D., & Wrobel, A. (2007). Amantadine as an additive treatment in patients suffering from drug-resistant unipolar depression. Pharmacological Reports, 59(6), 778-784.
33. Shrivastava, R., Shrivastava, S., Overweg, N., & Schmitt, M. (1995). Amantadine in the treatment of sexual dysfunction associated with selective serotonin reuptake inhibitors. Journal of Clinical Psychopharmacology, 15(1), 83-84.
34. Siever L. (1981). The effect of amantadine on prolactin levels and galactorrhea on neuroleptic-treated patients. Journal of Clinical Psychopharmacology, 1(1), 2-7.
35. Sodre, L., Bucker, J., Zortea, K., Sulzbach-Vianna, M., & Gama, C. (2010). Mania switch induced by amantadine in bipolar disorder: Report of three cases. Revista Brasileira de Psiquiatria, 32(4), 467-469.
36. Stryjer, R., Strous, R., Shaked, G., Bar, F., Feldman, B., Kotlerm M., Weizman, A. (2003). Amantadine as augmentation therapy in the management of treatment-resistant depression. International Clinical Psychopharmacology, 18(2), 93-96.
37. Yang, R., Mao, S., Li, R., & Zhao, Z. (2011). Several concerns arise when results are interpreted. Human Psychopharmacology: Clinical and Experimental, 26(1), 86-87.
38. Zdanys, K., & Tampi, R. (2008). A systematic review of off-label uses of memantine for psychiatric disorders. Progress in Neuro--Psychopharmacology and Biological Psychiatry, 32(6), 1362-1374.